Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Deferred Revenue (2016 - 2022)

Myriad Genetics has reported Current Deferred Revenue over the past 12 years, most recently at $200000.0 for Q3 2022.

  • Quarterly Current Deferred Revenue fell 98.26% to $200000.0 in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $200000.0 through Sep 2022, down 98.26% year-over-year, with the annual reading at $5.2 million for FY2021, 84.1% down from the prior year.
  • Current Deferred Revenue was $200000.0 for Q3 2022 at Myriad Genetics, down from $300000.0 in the prior quarter.
  • Over five years, Current Deferred Revenue peaked at $32.8 million in Q2 2020 and troughed at $200000.0 in Q3 2022.
  • The 5-year median for Current Deferred Revenue is $2.6 million (2018), against an average of $10.2 million.
  • Year-over-year, Current Deferred Revenue soared 1438.1% in 2020 and then crashed 98.67% in 2022.
  • A 5-year view of Current Deferred Revenue shows it stood at $2.4 million in 2018, then soared by 50.0% to $3.6 million in 2019, then soared by 808.33% to $32.7 million in 2020, then tumbled by 84.1% to $5.2 million in 2021, then plummeted by 96.15% to $200000.0 in 2022.
  • Per Business Quant, the three most recent readings for MYGN's Current Deferred Revenue are $200000.0 (Q3 2022), $300000.0 (Q2 2022), and $700000.0 (Q1 2022).